Azora Therapeutics, Inc. (DE) SEC filings AZR
Azora Therapeutics, Inc. (DE) has 575 filings in SEC EDGAR's recent list, going back to Mar 16, 2011. Its latest annual report, Form ARS, was filed on Aug 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (officer or director change, bylaw or fiscal year change, shareholder vote results, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 26, 2026 | — |
| EFFECT | Filing | Dec 17, 2025 | — |
| CORRESP | Letter to the SEC | Dec 15, 2025 | — |
| D | Filing | Dec 3, 2025 | — |
| DEFR14A | Proxy statement | Jun 27, 2025 | — |
| PRER14A | Proxy statement | Jun 17, 2025 | — |
| EFFECT | Filing | Jun 16, 2025 | — |
| CORRESP | Letter to the SEC | Jun 12, 2025 | — |
| CORRESP | Letter to the SEC | Jun 12, 2025 | — |
| EFFECT | Filing | Jun 9, 2025 | — |
| CORRESP | Letter to the SEC | Jun 6, 2025 | — |
| CORRESP | Letter to the SEC | Jun 5, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2025 | — |
| D | Filing | May 14, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2025 | — |
| DRSLTR | Filing | Mar 27, 2025 | — |
| DRS | Filing | Mar 27, 2025 | — |
| EFFECT | Filing | Dec 30, 2024 | — |
| CORRESP | Letter to the SEC | Dec 26, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2024 | — |
| EFFECT | Filing | Apr 19, 2024 | — |
| CORRESP | Letter to the SEC | Apr 17, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2024 | — |
| D | Filing | Mar 14, 2024 | — |
| EFFECT | Filing | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2024 | — |
| EFFECT | Filing | Nov 16, 2023 | — |
| CORRESP | Letter to the SEC | Nov 15, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2023 | — |
| NT 10-Q/A | Amendment no. 1 notification of late filing | Oct 30, 2023 | Jun 30, 2023 |
| D | Filing | Oct 26, 2023 | — |
| NT 10-Q | Notification of late filing | Aug 15, 2023 | Jun 30, 2023 |
| EFFECT | Filing | Jul 27, 2023 | — |
| 25-NSE | Delisting notice | Jul 27, 2023 | — |
| CORRESP | Letter to the SEC | Jul 25, 2023 | — |
| CORRESP | Letter to the SEC | Jul 13, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2023 | — |
| D | Filing | Jun 5, 2023 | — |
| D | Filing | Mar 6, 2023 | — |
| EFFECT | Filing | Jun 29, 2022 | — |
| EFFECT | Filing | Jun 29, 2022 | — |
| EFFECT | Filing | Apr 8, 2022 | — |
| CORRESP | Letter to the SEC | Apr 6, 2022 | — |
| CORRESP | Letter to the SEC | Mar 31, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 22, 2022 | — |
| CORRESP | Letter to the SEC | Mar 9, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 7, 2022 | — |
| D | Filing | Feb 17, 2022 | — |
| EFFECT | Filing | Dec 16, 2021 | — |
| CORRESP | Letter to the SEC | Dec 14, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2021 | — |
| DEFR14A | Definitive revised proxy statement | Aug 27, 2021 | — |
| EFFECT | Filing | Jul 29, 2021 | — |
| CORRESP | Letter to the SEC | Jul 27, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2021 | — |
| D | Filing | Jul 12, 2021 | — |
| RW | Registration withdrawal | Jun 28, 2021 | — |
| EFFECT | Filing | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 8, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2021 | — |
| EFFECT | Filing | May 26, 2021 | — |
| CORRESP | Letter to the SEC | May 24, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 26, 2021 | — |
| EFFECT | Filing | Apr 8, 2021 | — |
| EFFECT | Filing | Apr 8, 2021 | — |
| D | Filing | Mar 26, 2021 | — |
| EFFECT | Filing | Dec 15, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2020 | — |
| CORRESP | Letter to the SEC | Dec 14, 2020 | — |
| D | Filing | Nov 30, 2020 | — |
| D | Filing | Sep 25, 2020 | — |
| EFFECT | Filing | Jul 10, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2020 | — |
| CORRESP | Letter to the SEC | Jul 8, 2020 | — |
| D | Filing | Jun 17, 2020 | — |
| EFFECT | Filing | Apr 30, 2020 | — |
| CORRESP | Letter to the SEC | Apr 28, 2020 | — |
| EFFECT | Filing | Apr 27, 2020 | — |
| EFFECT | Filing | Apr 27, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2020 | — |
| EFFECT | Filing | Apr 1, 2019 | — |
| CORRESP | Letter to the SEC | Mar 28, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2019 | — |
| EFFECT | Filing | Feb 20, 2019 | — |
| CORRESP | Letter to the SEC | Feb 19, 2019 | — |
| CORRESP | Letter to the SEC | Feb 19, 2019 | — |
| CORRESP | Letter to the SEC | Feb 13, 2019 | — |
| CORRESP | Letter to the SEC | Feb 12, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2019 | — |
| DRS | Filing | Jan 7, 2019 | — |
| CERT | Filing | Jul 27, 2018 | — |
| EFFECT | Filing | Jul 26, 2018 | — |
| EFFECT | Filing | Jul 26, 2018 | — |
| CORRESP | Letter to the SEC | Jul 24, 2018 | — |
| CORRESP | Letter to the SEC | Jul 24, 2018 | — |
| 8-A12B/A | Amendment to form 8-a12b | Jul 23, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2018 | — |
| CORRESP | Letter to the SEC | Jul 3, 2018 | — |
| CORRESP | Letter to the SEC | Jun 25, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2018 | — |
| D | Filing | Jun 14, 2018 | — |
| D | Filing | Mar 13, 2018 | — |
| CORRESP | Letter to the SEC | Dec 19, 2017 | — |
| CORRESP | Letter to the SEC | Dec 15, 2017 | — |
| CORRESP | Letter to the SEC | Dec 15, 2017 | — |
| 8-A12B | Form 8-a12b | Dec 11, 2017 | — |
| D | Filing | Dec 5, 2017 | — |
| CORRESP | Letter to the SEC | Oct 25, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2017 | — |
| CORRESP | Letter to the SEC | Sep 25, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2017 | — |
| CORRESP | Letter to the SEC | Sep 19, 2017 | — |
| D | Filing | Aug 31, 2017 | — |
| DRSLTR | Filing | Jul 28, 2017 | — |
| DRS/A | Filing | Jul 28, 2017 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2017 | — |
| DRSLTR | Filing | Jun 21, 2017 | — |
| DRS/A | Filing | Jun 21, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2017 | — |
| D | Filing | May 16, 2017 | — |
| DRS | Filing | May 12, 2017 | — |
| D | Filing | Oct 2, 2013 | — |
| D | Filing | Mar 16, 2011 | — |
Showing 124 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AZR (Nasdaq), ADIL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Encino, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1513525
- Former names
- ADIAL PHARMACEUTICALS, INC. (until Oct 30, 2026); Adial Pharmaceuticals, L.L.C. (until Sep 28, 2017); ADial Pharmaceuticals, L.L.C. (until Sep 28, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.